Lead Product(s) : Dodecafluoropentane
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : University of Glasgow | NuvOx Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
NanO2 in Large VessEL Occlusion Stroke (NOVEL)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 12, 2025
Lead Product(s) : Dodecafluoropentane
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : University of Glasgow | NuvOx Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dodecafluoropentane
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Dose Escalation Study of NanO2 in Patients With Mild Respiratory Distress
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 26, 2024
Lead Product(s) : Dodecafluoropentane
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dodecafluoropentane
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : University of Arkansas | Stanford University | Washington Regional Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
NanO2 for Large Vessel Occlusion Stroke
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 25, 2022
Lead Product(s) : Dodecafluoropentane
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : University of Arkansas | Stanford University | Washington Regional Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dodecafluoropentane
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of NanO2â„¢ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 05, 2019
Lead Product(s) : Dodecafluoropentane
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable